These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19614621)

  • 1. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
    Humbert M; de Blay F; Garcia G; Prud'homme A; Leroyer C; Magnan A; Tunon-de-Lara JM; Pison C; Aubier M; Charpin D; Vachier I; Purohit A; Gineste P; Bader T; Moussy A; Hermine O; Chanez P
    Allergy; 2009 Aug; 64(8):1194-201. PubMed ID: 19614621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
    Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
    Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.
    Davidescu L; Ursol G; Korzh O; Deshmukh V; Kuryk L; Nortje MM; Godlevska O; Devouassoux G; Khodosh E; Israel E; Moussy A; Mansfield CD; Hermine O; Chanez P
    J Asthma Allergy; 2022; 15():737-747. PubMed ID: 35698580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
    Vermersch P; Benrabah R; Schmidt N; Zéphir H; Clavelou P; Vongsouthi C; Dubreuil P; Moussy A; Hermine O
    BMC Neurol; 2012 Jun; 12():36. PubMed ID: 22691628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
    Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
    PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
    Soria JC; Massard C; Magné N; Bader T; Mansfield CD; Blay JY; Bui BN; Moussy A; Hermine O; Armand JP
    Eur J Cancer; 2009 Sep; 45(13):2333-41. PubMed ID: 19541476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
    Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
    Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
    Littner MR; Leung FW; Ballard ED; Huang B; Samra NK;
    Chest; 2005 Sep; 128(3):1128-35. PubMed ID: 16162697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of masitinib mesylate in healthy cats.
    Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
    J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
    Busse WW; Wenzel SE; Meltzer EO; Kerwin EM; Liu MC; Zhang N; Chon Y; Budelsky AL; Lin J; Lin SL
    J Allergy Clin Immunol; 2013 Feb; 131(2):339-45. PubMed ID: 23174659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
    Piette F; Belmin J; Vincent H; Schmidt N; Pariel S; Verny M; Marquis C; Mely J; Hugonot-Diener L; Kinet JP; Dubreuil P; Moussy A; Hermine O
    Alzheimers Res Ther; 2011 Apr; 3(2):16. PubMed ID: 21504563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
    Paul C; Sans B; Suarez F; Casassus P; Barete S; Lanternier F; Grandpeix-Guyodo C; Dubreuil P; Palmérini F; Mansfield CD; Gineste P; Moussy A; Hermine O; Lortholary O
    Am J Hematol; 2010 Dec; 85(12):921-5. PubMed ID: 21108325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.